[To learn English]
Swiss pharmaceutical giant Roche has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics of up to $2.3 billion, the company said on Monday.
The deal focuses on blood cancer drug bexobrutideg, which degrades targeted proteins and is planned to enter a phase III clinical trial initiation for chronic lymphocytic leukaemia (CLL) in the summer.
瑞士制药巨头罗氏已与 Nurix Therapeutics 达成一项独家许可与合作协议，交易总额最高达 23 亿美元，该公司周一表示。
该交易聚焦于血癌药物 bexobrutideg，该药通过降解靶向蛋白质发挥作用，计划于今年夏季启动针对慢性淋巴细胞白血病（CLL）的 III 期临床试验。
LearnEnglish Leave a remark